Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)

Fulgent Genetics (FLGT) has received a reiterated 'Buy' rating with a $34 fair value, despite trading around $21-22, below its $26/share cash value. The analyst cites accelerating core lab services revenue, projected at $320 million for 2025 (14% growth), alongside improving gross margins targeting 40% and strong performance in precision diagnostics and anatomic pathology. While the market remains skeptical, the company's Fulgent Pharma segment shows encouraging Phase 2 progress with its FID-007 oncology asset, though conservatively valued at $0 in the current model due to uncertainty. The thesis anticipates a re-rating driven by sustained lab services growth and potential pharma catalysts, despite near-term range-bound trading.

Analysis

Fulgent Genetics (FLGT) presents a significant valuation disconnect, with its stock trading between $21-$22, notably below its cash value of $26 per share. This market pessimism persists despite accelerating fundamentals in its core Laboratory Services business, which is projected to achieve $320 million in revenue for 2025, representing 14% year-over-year growth. This growth is driven by strong performance in its Precision Diagnostics division (+16%) and a successful turnaround in Anatomic Pathology (+11%). Concurrently, gross margins are expanding, tracking towards 40% in 2025 from 38% in FY24, and the company is demonstrating operating leverage with underlying operating expenses rising just 4% against a 15% revenue increase in H1-2025. The market's valuation appears to assign a negative value to the core business while also pricing in significant cash burn from the Fulgent Pharma segment. This pharma division, while speculative and conservatively valued at zero in the analyst's model, shows encouraging progress with its lead asset, FID-007, which is proceeding through a Phase 2 trial under a cost-and-time-efficient 505(b)(2) pathway. Key risks are less macroeconomic and more centered on corporate governance and capital allocation, specifically the potential for value-destructive M&A by the controlling CEO, although recent opportunistic share buybacks under a $140 million authorization provide some support.

Key Decisions for Investors

• Given the stock is trading below its cash per share value of $26, investors could view the current price as a compelling entry point, as it implies the market is assigning a negative value to a growing and profitable core lab business.
• Investors should closely monitor core lab revenue growth and gross margin expansion in upcoming quarters, as sustained performance above 10% and 40% respectively would validate the fundamental bull thesis and pressure the market to re-rate the stock.
• Treat the Fulgent Pharma pipeline, particularly the FID-007 asset, as a high-risk, high-reward call option; the expected data readout in 2026 is a key potential catalyst that could unlock significant value or confirm the market's skepticism.
• Be mindful of the corporate governance risk associated with the CEO's majority control, and consider any new, large-scale M&A announcements as a potential trigger for a thesis re-evaluation.